ArticleScientific reports2025
Identification and validation of palmitoylation metabolism related biomarkers in osteoarthritis using transcriptomic and single cell RNA sequencing analyses.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Osteoarthritis (OA) is a degenerative joint disease characterized by cartilage degradation and chronic inflammation, leading to pain and disability. Protein palmitoylation, a reversible lipid modification, plays a crucial role in cellular functions, but its involvement in OA remains unclear. To explore palmitoylation-related biomarkers in OA, transcriptomic and single-cell RNA sequencing analyses were performed. Machine learning algorithms and differential expression analysis identified BUB1B and KIF15 as key biomarkers, which were consistently upregulated in OA cartilage with strong diagnostic performance. Their elevated expression was validated in clinical OA samples using RT-qPCR. Functional enrichment analysis linked these biomarkers to mitotic division, chromosome segregation, and spliceosome pathways, while immune infiltration analysis suggested a role in immune modulation, with BUB1B correlating positively with immature dendritic cells and negatively with activated B cells. Further investigation identified the lncRNA XIST as a potential upstream regulator, and molecular docking analysis highlighted cyclosporine as a promising therapeutic candidate. Single-cell RNA sequencing demonstrated their differential expression across fibrocartilage, regulatory, proliferative, and homeostatic chondrocytes, suggesting cell-type-specific roles in OA progression. These findings provide new insights into the involvement of palmitoylation in OA and highlight BUB1B and KIF15 as potential biomarkers with diagnostic and therapeutic relevance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.